S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.

"the transcriptomic profile of ssc patients was retrieved from a publicly available dataset of north american ssc patient cohort (ncbi/geo/gse59787) consisting of 143 ssc patients and 22 healthy individuals [ ]."

"Disclosure statement : J.H.W.D. has consultancy relationships with AbbVie, Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Janssen, Novartis, Pfizer and UCB. J.H.W.D. has received research funding from Anamar, ARXX Therapeutics, BMS, Bayer Pharma, Boehringer Ingelheim, Cantargia, Celgene, CSL Behring, Galapagos, GSK, Inventiva, Kiniksa, Sanofi-Aventis, RedX and UCB. J.H.W.D. is stock owner of 4D Science. The 6B12 anti-S100A4 monoclonal antibody was provided by Arxx Therapeutics."

"Funding This work was supported by the Ministry of Health of the Czech Republic [023728] and Ministry of Education Youth and Sports of the Czech Republic [SVV 260638]. This study was also supported by project-specific funding of Arxx Therapeutics. J.H.W.D. was supported by grants DI 1537/14-1, DI 1537/17-1, DI 1537/20–1, DI 1537/22-1 and DI 1537/23-1, of the German Research Foundation, SFB CRC1181 (project C01) and SFB TR221/project number 324392634 (B04) of the German Research Foundation, grant A79 of the IZKF in Erlangen, grant 2013.056.1 of the Wilhelm-Sander-Foundation, grants 2014_A47 and 2014_A184 of the Else-Kröner-Fresenius-Foundation, BMBF, MASCARA program, TP 2 (01EC1903A) and a Career Support Award of Medicine of the Ernst Jung Foundation. Disclosure statement: J.H.W.D. has consultancy relationships with AbbVie, Active Biotech, Anamar, ARXX, AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Celgene, Galapagos, GSK, Inventiva, Janssen, Novartis, Pfizer and UCB. J.H.W.D. has received research funding from Anamar, ARXX Therapeutics, BMS, Bayer Pharma, Boehringer Ingelheim, Cantargia, Celgene, CSL Behring, Galapagos, GSK, Inventiva, Kiniksa, Sanofi-Aventis, RedX and UCB. J.H.W.D. is stock owner of 4D Science. The 6B12 anti-S100A4 monoclonal antibody was provided by Arxx Therapeutics. Patient consent for publication: Not required. Provenance and peer review: Not commissioned, externally peer-reviewed."